Skip to main content
. 2018 Apr 3;10(3):244–252. doi: 10.4168/aair.2018.10.3.244

Table 1. Comparisons of clinical characteristics between “Treatable AD” and “Recalcitrant AD”.

Clinical parameters Treatable AD (n=249) Recalcitrant AD (n=32) OR (95% CI) P Adjusted OR (95% CI)a Adjusted Pa
Age (year) 15.3±15.3 31.3±16.7
Sex
 Male 146 (58.6%) 20 (62.5%) Reference - Reference -
 Female 103 (41.4%) 12 (37.5%) 0.85 (0.39–1.79) 0.676 1.05 (0.46–2.38) 0.896
Onset (year) 9.5±14.4 22.4±20.9 1.04 (1.02–1.06) <0.001 0.97 (0.93–1.02) 0.216
Duration (months) 69.6±85.5 101.3±100.1 1.00 (1.00–1.01) 0.059 1.00 (1.00–1.01) 0.321
Type of atopic dermatitis
 Intrinsic 47 (19.3%) 2 (6.2%) Reference - Reference -
 Extrinsic 197 (80.7%) 30 (93.8%) 3.58 (1.03–22.61) 0.089 1.82 (0.48–11.87) 0.441
Self-reported history of atopic diseases 128 (51.4%) 19 (59.4%) 1.38 (0.66–2.98) 0.400 1.80 (0.80–4.24) 0.162
Self-reported family history of atopic diseases 184 (73.9%) 26 (81.2%) 1.53 (0.64–4.26) 0.370 12.37 (3.17–62.34) <0.001
Initial EASI 8.6±7.1 19.5±9.0 1.14 (1.09–1.19) <0.001 1.13 (1.09–1.19) <0.001
Associated skin findings
 Impetigo 23 (9.2%) 3 (9.4%) 1.02 (0.23–3.16) 0.980 1.24 (0.26–4.34) 0.756
 Prurigo nodularis 31 (12.4%) 3 (9.4%) 0.73 (0.17–2.21) 0.617 0.26 (0.06–1.13) 0.073
 Nummular eczema 28 (11.2%) 11 (34.4%) 4.13 (1.76–9.37) <0.001 2.76 (1.08–6.65) 0.027
Serum IgE level (IU/mL)
 Total IgE 573.5±859.6 1,384.3±1,194.7 <0.001
  <100 96 (38.6%) 3 (9.4%) Reference - Reference -
  ≥100, <1,000 110 (44.2%) 15 (46.9%) 4.38 (1.39–19.25) 0.023 2.68 (0.80–12.22) 0.142
  ≥1,000 43 (17.3%) 14 (43.8%) 10.42 (3.20–46.90) <0.001 5.55 (1.58–25.99) 0.013
 Allergen-specific IgE for Dermatophagoides farinae 179.6±975.8 319.3±1,064.5 <0.001
  <0.70 (0, 1+) 139 (55.8%) 5 (15.6%) Reference - Reference -
  ≥0.70, <50.00 (2+, 3+, 4+) 69 (27.7%) 9 (28.1%) 3.63 (1.21–12.19) 0.026 2.15 (0.66–7.61) 0.212
  ≥50.00 (5+, 6+) 41 (16.5%) 18 (56.2%) 12.20 (4.56–38.81) <0.001 11.16 (3.94–37.68) <0.001
 Allergen-specific IgE for Dermatophagoides pteronyssinus 78.0±373.9 566.6±1,344.6 <0.001
  <0.70 (0, 1+) 147 (59.0%) 6 (18.8%) Reference - Reference -
  ≥0.70, <50.00 (2+, 3+, 4+) 60 (24.1%) 6 (18.8%) 2.45 (0.74–8.12) 0.134 1.55 (0.43–5.47) 0.492
  ≥50.00 (5+, 6+) 42 (16.9%) 20 (62.5%) 11.67 (4.64–33.63) <0.001 10.82 (4.04–33.71) <0.001

aAdjusted by subjects' age.

AD, atopic dermatitis; OR, odds ratio; 95% CI, 95% confidential interval; EASI, Eczema Area Severity Index; IgE, immunoglobulin E.

HHS Vulnerability Disclosure